替诺福韦治疗肝硬化患者的临床效果

Clinical Effect of Tenofovir on Patients With Cirrhosis

目的探讨替诺福韦治疗对肝硬化患者临床效果。方法选取2018年4月—2019年3月入住医院的乙肝肝硬化患者118例,应用随机抽签法,随机分为两组,对照组59例应用拉米夫定治疗,研究组59例应用替诺福韦进行治疗。对两组患者的肝功能以及肝纤维指标进行比较,评定其治疗效果。结果研究组治疗后ALT(49.2±8.7)U/L及TBIL(33.1±5.7)mol/L低于对照组的(67.5±9.9)U/L、(43.6±6.5)mol/L;研究组的ALB(43.2±4.7)g/L高于对照组的(36.9±3.9)g/L(P<0.05);研究组肝纤维指标优于对照组(P<0.05)。结论本研究中应用替诺福韦对肝硬化患者实施治疗,患者肝功能及肝纤维指标均获得极大改善,疗效理想。

Objective To explore the clinical effect of tenofovir treatment on patients with liver cirrhosis.Methods 118 patients with hepatitis B liver cirrhosis who were admitted to the hospital from April 2018 to March 2019 were selected and randomly divided into two groups by drawing method.59 cases in the control group were treated with lamivudine,and 59 cases in the study group were treated with tenofovir for treatment.The liver function and liver fiber indexes of the two groups of patients were compared to evaluate the therapeutic effect.Results After treatment,ALT(49.2±8.7)U/L and TBIL(33.1±5.7)mol/L of the study group were lower than those of the control group(67.5±9.9)U/L,(43.6±6.5)mol/L;the ALB of the study group(43.2±4.7)g/L was higher than the control group(36.9±3.9)g/L(P<0.05);the liver fiber index of the study group was better than the control group(P<0.05).Conclusion In this study,tenofovir was used to treat patients with liver cirrhosis,and the liver function and liver fiber indexes of the patients were greatly improved.The curative effect is idea.